Dr. Oscar A. Lenis-Rojas, Dr. Catarina Roma-Rodrigues, Beatriz Carvalho, Vasco Andrade, Dr. Sofia Friães, Pablo Cabezas-Sainz, Dr. Jhonathan Angel Araujo Fernández, Sabela Fernández Vila, Dr. Álvaro J. Arana, Dr. Laura Sanchez, Dr. Pedro V. Baptista, Dr. Clara S. B. Gomes, Dr. Alexandra R. Fernandes, Dr. Beatriz Royo
{"title":"三唑衍生钌（II）配合物作为癌症治疗的新候选者。","authors":"Dr. Oscar A. Lenis-Rojas, Dr. Catarina Roma-Rodrigues, Beatriz Carvalho, Vasco Andrade, Dr. Sofia Friães, Pablo Cabezas-Sainz, Dr. Jhonathan Angel Araujo Fernández, Sabela Fernández Vila, Dr. Álvaro J. Arana, Dr. Laura Sanchez, Dr. Pedro V. Baptista, Dr. Clara S. B. Gomes, Dr. Alexandra R. Fernandes, Dr. Beatriz Royo","doi":"10.1002/cplu.202400775","DOIUrl":null,"url":null,"abstract":"<p>The first examples of Ru(II) η<sup>6</sup>-arene (benzene and <i>p</i>-cymene) complexes containing a bidentate triazolylidene-triazolide ligand have been prepared and fully characterized. Their antiproliferative effect has been investigated against tumour cells A2780 (ovarian carcinoma), HCT116 (colorectal carcinoma), and HCT116dox (colorectal carcinoma resistant to doxorubicin), and in human dermal fibroblasts. The Ru complex bearing the <i>p</i>-cymene arene group exhibited a stronger antiproliferative effect across all tested cell lines, while the benzene-containing complex displayed higher selectivity toward tumor cells. Both complexes induced apoptosis, likely through ROS production (in the benzene complex), and inhibited tumorigenic processes, including cell migration and angiogenesis. In zebrafish models, they showed strong selectivity for cancer cells with minimal toxicity to healthy cells, effectively reducing the proliferation of HCT116 colorectal cancer cells. This study provides the first <i>in vivo</i> evidence of the anticancer potential of Ru triazolylidenes in zebrafish models.</p>","PeriodicalId":148,"journal":{"name":"ChemPlusChem","volume":"90 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Triazole-Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy\",\"authors\":\"Dr. Oscar A. Lenis-Rojas, Dr. Catarina Roma-Rodrigues, Beatriz Carvalho, Vasco Andrade, Dr. Sofia Friães, Pablo Cabezas-Sainz, Dr. Jhonathan Angel Araujo Fernández, Sabela Fernández Vila, Dr. Álvaro J. Arana, Dr. Laura Sanchez, Dr. Pedro V. Baptista, Dr. Clara S. B. Gomes, Dr. Alexandra R. Fernandes, Dr. Beatriz Royo\",\"doi\":\"10.1002/cplu.202400775\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The first examples of Ru(II) η<sup>6</sup>-arene (benzene and <i>p</i>-cymene) complexes containing a bidentate triazolylidene-triazolide ligand have been prepared and fully characterized. Their antiproliferative effect has been investigated against tumour cells A2780 (ovarian carcinoma), HCT116 (colorectal carcinoma), and HCT116dox (colorectal carcinoma resistant to doxorubicin), and in human dermal fibroblasts. The Ru complex bearing the <i>p</i>-cymene arene group exhibited a stronger antiproliferative effect across all tested cell lines, while the benzene-containing complex displayed higher selectivity toward tumor cells. Both complexes induced apoptosis, likely through ROS production (in the benzene complex), and inhibited tumorigenic processes, including cell migration and angiogenesis. In zebrafish models, they showed strong selectivity for cancer cells with minimal toxicity to healthy cells, effectively reducing the proliferation of HCT116 colorectal cancer cells. This study provides the first <i>in vivo</i> evidence of the anticancer potential of Ru triazolylidenes in zebrafish models.</p>\",\"PeriodicalId\":148,\"journal\":{\"name\":\"ChemPlusChem\",\"volume\":\"90 5\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemPlusChem\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cplu.202400775\",\"RegionNum\":4,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemPlusChem","FirstCategoryId":"92","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cplu.202400775","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Triazole-Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy
The first examples of Ru(II) η6-arene (benzene and p-cymene) complexes containing a bidentate triazolylidene-triazolide ligand have been prepared and fully characterized. Their antiproliferative effect has been investigated against tumour cells A2780 (ovarian carcinoma), HCT116 (colorectal carcinoma), and HCT116dox (colorectal carcinoma resistant to doxorubicin), and in human dermal fibroblasts. The Ru complex bearing the p-cymene arene group exhibited a stronger antiproliferative effect across all tested cell lines, while the benzene-containing complex displayed higher selectivity toward tumor cells. Both complexes induced apoptosis, likely through ROS production (in the benzene complex), and inhibited tumorigenic processes, including cell migration and angiogenesis. In zebrafish models, they showed strong selectivity for cancer cells with minimal toxicity to healthy cells, effectively reducing the proliferation of HCT116 colorectal cancer cells. This study provides the first in vivo evidence of the anticancer potential of Ru triazolylidenes in zebrafish models.
期刊介绍：
ChemPlusChem is a peer-reviewed, general chemistry journal that brings readers the very best in multidisciplinary research centering on chemistry. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
Fully comprehensive in its scope, ChemPlusChem publishes articles covering new results from at least two different aspects (subfields) of chemistry or one of chemistry and one of another scientific discipline (one chemistry topic plus another one, hence the title ChemPlusChem). All suitable submissions undergo balanced peer review by experts in the field to ensure the highest quality, originality, relevance, significance, and validity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
